Patient-reported outcomes with nivolumab plus cabozantinib in advanced kidney cancer

Ongoing results from the phase 3 CheckMate-9ER clinical trial with nivolumab plus cabozantinib have been published in The Lancet Oncology this week. Previous trial results have shown that the nivolumab/cabozantinib combination doubled the average time to when the treatment stopped working and the cancer started growing again (progression-free survival) compared to sunitinib and nearly twice as many previously untreated renal cell carcinoma (RCC) patients responded […]

read more

Atezolizumab plus bevacizumab does not improve survival in kidney cancer

Results from the IMmotion151 phase III clinical trial were published in JAMA Oncology this week and showed that a combination of atezolizumab and bevacizumab did not improve overall survival time compared with sunitinib in patients with previously untreated, metastatic renal cell carcinoma (RCC). The researchers said they “do not have a clear explanation” for these […]

read more

Misinformation in the diagnosis and treatment of kidney cancer

Dena Battle from KCCure, an American kidney cancer patient organisation, describes the difference between misinformation and disinformation. She tries to dispel the common myths regarding the diagnosis and treatment of kidney cancer and speaks about what is causing the distribution of misinformation among patient communities. A number of factors are involved, such as new data, […]

read more

Stereotactic radiation can slow progression of kidney cancer

A new study from the USA shows that highly focused radiation called stereotactic ablative radiotherapy (SABR) to isolated kidney cancer metastases that grow despite treatment with medication can slow progression of the disease. This can save the use of other drugs for treating the kidney cancer down the line. Metastatic kidney cancer is difficult to […]

read more

Adjuvant pembrolizumab gets positive opinion from the European CHMP

We have just learnt that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), is recommending approval of pembrolizumab for the adjuvant treatment of people with intermediate to high risk renal cell carcinoma (RCC) following nephrectomy. The CHMP positive opinion will now be reviewed by the […]

read more

Get involved: Research to understand what outcomes matter most to patients

Researchers from Aberdeen University are involved in a piece of research to help understand what outcomes matter most to patients living with and beyond kidney cancer, and how COVID-19 has impacted on outcomes they find important. They are now ready to interview patients and would like your help to share the following invitation to patients who […]

read more
Showing 1 to 6 of 1165 results
  TOP